Companies › Longbio Pharma
2 active drug programs in 5 registered trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Immunology, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LP-003 | – | Phase 3 | Seasonal Allergic Rhinitis; Allergic Asthma; Allergic Diseases; Chronic Spontaneous Urticaria | Nov 2026 |
| LP-005 Injection Complement pathway inhibitor | – | Phase 2 | PNH - Paroxysmal Nocturnal Hemoglobinuria | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07148557 | LP-003 | Phase 1 | Allergic Diseases | Immunology | May 2026 |
| NCT06604949 | LP-003 | Phase 1 | Chronic Spontaneous Urticaria | Immunology | Nov 2026 |
| NCT07291284 | LP-003 | Phase 3 | Seasonal Allergic Rhinitis | Immunology | Dec 2026 |
| NCT07342803 | LP-003 | Phase 2 | Allergic Asthma | Immunology | Dec 2027 |
| NCT07212426 | LP-005 Injection | Phase 2 | PNH - Paroxysmal Nocturnal Hemoglobinuria | Hematology | Mar 2028 |
No annotated target.
–
Octapharma Kedrion Paradigm Biopharmaceuticals Arthrosi Therapeutics Disc Medicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.